← Eichor
Study identifier: NCT06845644 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients

Condition: Charcot-Marie-Tooth Neuropathy Type 1A · Hereditary Transthyretin Amyloid Neuropathy · Acquired Demyelinating Neuropathy  ·  Sponsor: Assistance Publique Hopitaux De Marseille

PhaseNA
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The pathophysiological process common to neuropathies is fatty replacement of muscle tissue, more commonly known as intramuscular fat fraction (F.F). MRI is an imaging technique that enables us to distinguish between muscle and fat tissue, and thus to objectify in vivo structural changes within nerves and muscles in neuropathic patients. In addition to visualizing these changes, quantitative neuromuscular MRI (qMRI) can be used to quantify a number of biomarkers associated with these pathophysiological processes. Over the past few years, this procedure has become a relevant tool in a number of neuromuscular pathologies, such as acquired and hereditary neuropathies. Thanks to its non-ionizing nature and its ability to explore tissues in three dimensions, MRI is the technique of choice for evaluating these diseases, complementing the clinical and electrophysiological scores available. In a context where numerous therapic strategies are being evaluated for the treatment of peripheral nervous system diseases, the clinical and electrophysiological scores currently available are proving inadequate for the detection of early change or a positive therapeutic effect. On the basis of a limited number of studies, quantitative MRI could provide much more sensitive therapeutic monitoring data over short periods of time which is crucial for future therapeutic trials. The most interesting MRI biomarker to date would therefore be the FF, which represents the percentage of fatty infiltratio…

This description comes directly from the study's public registry record.

Talk to the study team

Etienne FORTANIER, MD  ·  04 91 38 65 79  ·  etienne.fortanier@ap-hm.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Assistance - Publique Hôpitaux de MarseilleMarseille, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06845644